At Sanofi’s inaugural Global Rare Impact Awards ceremony held on November 14, 2025, in Vienna, three extraordinary leaders were recognized for their dedication to the rare disease community — including two remarkable advocates deeply connected to the Pompe community.
Last week, at our Inaugural Global Rare Impact Awards ceremony November 14, 2025 in Vienna, we honored three remarkable pioneers:
Tiffany House — A visionary leader in global patient advocacy, particularly in the Pompe community, setting the gold standard for collaborative advocacy leadership worldwide.
Maryze Schoneveld van der Linde — A beacon of hope for rare disease patients in developing countries, distinguished board member of the International Pompe Association, and tireless advocate for patient needs globally.
Dr. I. C. Verma — Known as the “Father of Genetics” in India, Dr. Verma established two groundbreaking genetic centers and pioneered affordable genetic testing. His compassionate access program has helped treat over 300 patients with lysosomal storage disorders.
We are pleased to recognize these exceptional individuals who have dedicated their lives to transforming the rare disease landscape and those who have demonstrated outstanding leadership and unwavering commitment to the rare disease community for more than two decades.
This award embodies Sanofi’s commitment to recognizing those remarkable individuals who have dedicated their lives to advancing rare disease causes. Their tireless efforts have created lasting changes in the rare disease community, improving countless lives worldwide.
Originally shared by Alaa Hamed, MD, MPH, MBA — Global Head of Medical Affairs, Rare Diseases at Sanofi.
Honoring Two Leaders in Pompe Advocacy
The AMDA is honored to see our late president, Tiffany House, recognized alongside Maryze Schoneveld van der Linde of the International Pompe Association (IPA). Both women dedicated their lives to advancing patient advocacy and building a stronger, more connected global community for those living with Pompe disease. Their vision, compassion, and leadership continue to inspire our work and the Pompe community worldwide.
Originally announced by Sanofi Rare Diseases (LinkedIn post dated November 14, 2025).
